These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 33052242)

  • 1. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic importance of
    Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy.
    Grewal AS; Min EJ; Long Q; Grewal SK; Jain V; Levin WP; Cengel KA; Swisher-McClure S; Aggarwal C; Bauml JM; Singh A; Ciunci C; Cohen RB; Langer C; Feigenberg SJ; Berman AT
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):358-368. PubMed ID: 31654783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
    Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
    Kozak MM; Murphy JD; Schipper ML; Donington JS; Zhou L; Whyte RI; Shrager JB; Hoang CD; Bazan J; Maxim PG; Graves EE; Diehn M; Hara WY; Quon A; Le QT; Wakelee HA; Loo BW
    J Thorac Oncol; 2011 May; 6(5):920-6. PubMed ID: 21774104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
    Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS
    Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
    Kim N; Kim JS; Geol Lee C
    PLoS One; 2020; 15(7):e0236350. PubMed ID: 32687531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
    Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
    PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
    Carvalho S; Leijenaar RTH; Troost EGC; van Timmeren JE; Oberije C; van Elmpt W; de Geus-Oei LF; Bussink J; Lambin P
    PLoS One; 2018; 13(3):e0192859. PubMed ID: 29494598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?
    Tankyevych O; Tixier F; Antonorsi N; Filali Razzouki A; Mondon R; Pinto-Leite T; Visvikis D; Hatt M; Cheze Le Rest C
    Methods; 2021 Apr; 188():73-83. PubMed ID: 33197567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.